BrainSeq: Neurogenomics to Drive Novel Target Discovery for Neuropsychiatric Disorders

详细信息    查看全文

• 作者：BrainSeq ; A Human Brain Genomics Consortium ; ; ^{drweinberger@libd.org" class="auth_mail" title="E-mail the corresponding author}Christian R. Schubert ; Patricio O&rsquo ; Donnell ; Jie Quan ; Jens R. Wendland ; Hualin S. Xi ; Ashley R. Winslow ; Enrico Domenici ; Laurent Essioux ; Tony Kam-Thong ; David C. Airey ; John N. Calley ; David A. Collier ; Hong Wang ; Brian Eastwood ; Philip Ebert ; Yushi Liu ; Laura Nisenbaum ; Cara Ruble ; James E. Scherschel ; Ryan Matthew Smith ; Hui-Rong Qian ; Kalpana Merchant ; Michael Didriksen ; Mitsuyuki Matsumoto ; Takeshi Saito ; Nicholas J. Brandon ; Alan J. Cross ; Qi Wang ; Husseini Manji ; Hartmuth Kolb ; Maura Furey ; Wayne C. Drevets ; Joo Heon Shin ; Andrew E. Jaffe ; Yankai Jia ; Richard E. Straub ; Amy Deep-Soboslay ; Thomas M. Hyde ; Joel E. Kleinman ; Daniel R. Weinberger
• 刊名：Neuron
• 出版年：2015
• 出版时间：16 December 2015
• 年：2015
• 卷：88
• 期：6
• 页码：1078-1083
• 全文大小：797 K

文摘

We outline an ambitious project to characterize the genetic and epigenetic regulation of multiple facets of transcription in distinct brain regions across the human lifespan in samples of major neuropsychiatric disorders and controls. Initially focused on schizophrenia and mood disorders, the goal of this consortium is to elucidate the underlying molecular mechanisms of genetic associations with the goal of identifying novel therapeutic targets. The consortium currently consists of seven pharmaceutical companies and a not-for-profit medical research institution working as a precompetitive team to generate and analyze publicly available archival brain genomic data related to neuropsychiatric illness.